Targeted CRISPR Gene Repression for HBV Replication Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B infection, such as nucleoside analogs, PEGylated interferon, and siRNA, face challenges in efficacy and stability, necessitating improved methods for reducing Hepatitis B viral replication and expression.
Innovation Solution
An epigenetic-modifying DNA-targeting system using CRISPR-Cas/guide RNA systems to repress Hepatitis B viral gene transcription by binding to specific target sites, employing fusion proteins with DNA-binding domains and transcriptional repressor effector domains to reduce HBV replication and protein levels without introducing genetic disruptions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (nucleoside analogs, PEGylated interferon, siRNA) are used to suppress viral DNA transcription, then Hepatitis B viral replication is reduced, but efficacy and stability challenges remain
Solution Approach 1:
The patent replaces conventional chemical treatments (nucleoside analogs, interferon, siRNA) with an epigenetic-modifying DNA-targeting system that uses fusion proteins combining DNA-binding domains (such as dCas9) with transcriptional repressor effector domains. This substitution enables more reliable and stable suppression of HBV transcription by directly modifying chromatin structure and transcriptional machinery rather than relying on viral polymerase inhibition or interferon signaling pathways.
Solution Approach 2:
The patent changes the mechanism of action from direct viral polymerase inhibition to epigenetic modification of host chromatin. By introducing fusion proteins that combine DNA-binding domains with transcriptional repressor effector domains, the system modifies the epigenetic state of HBV DNA, leading to stable long-term transcriptional repression without the efficacy and stability limitations of conventional treatments.
2Reliability
If DNA-targeting systems bind to multiple sites in HBV DNA sequence, then transcriptional repression is enhanced, but system complexity increases
Solution Approach 1:
The patent employs multiple DNA-targeting modules, each consisting of a fusion protein with a specific DNA-binding domain and transcriptional repressor effector domain, that bind to different target sites within the HBV genome. This segmentation allows independent targeting of multiple transcriptional units, enhancing overall repression efficacy while maintaining modular system design that manages complexity through standardized components.
Solution Approach 2:
The patent uses a universal fusion protein platform where the same basic architecture (DNA-binding domain + transcriptional repressor effector domain) can be applied to multiple target sites. The modular design allows the system to target different HBV genes and regulatory elements using the same fundamental mechanism, reducing overall system complexity compared to requiring separate specialized systems for each target.
Data Source
AI summary
Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and/or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.